Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Commented On
ISNVD 2016 Conference
The Orion Conference: Turning Big Data Into Knowledge
How We Manage the Weekly List of MS Papers
Epo short peptide...anyone know about this?
Newly Dianosed .. need clearer direction on next steps of the process.
Hematopoietic Stem Cell Transplant in MS: Third Study Reports Positive Results
Spinal Cord, Retinal Measures Independently Relate to MS Disability
A Diagnosis of End-Term MS
Research on Primary Progressive MS
rhGH effect on remyelination
Glatiramer Acetate and the Interferon Betas Are Clinically Similar
Corpus Callosum Cross-Section Correlated With Cognitive Decline
Study Probes “No Evidence of Disease Activity” in MS Patients
Axon Transport Deficits: Neurodegeneration’s First Sign?
The Power of Positive Thinking
MRI Education May Benefit MSers
Does Diet Matter in Multiple Sclerosis?
Fatigue: New Mouse Model in the Works
New iPad App Tracks MS Patient Course
No Causal Link Found Between Vaccines and MS
MS Family Planning 201: Breastfeeding, DMTs, and the Risk of Postpartum Relapse
Phase 2 Trial Suggests RPC1063 Is as Effective as—and Safer Than—Fingolimod
Is Cognitive MS a Distinct Entity?
159 Genetic Variants Now Known to Be Associated With MS
Why have annualized relapse rates in RRMS trials decreased?